The company had posted a net loss of Rs 10.6 crore for the corresponding period of the previous fiscal year, it said in a filing to the BSE.
Consolidated total income from operations rose to Rs 954.1 crore in the quarter under consideration, as against Rs 796.2 crore in the corresponding period a year ago.
Commenting on the development, Biocon chairperson and MD Kiran Mazumdar-Shaw said: "Our performance in Q2 FY17, was led by strong growth across Small Molecules, Biologics and Research Services."
Expansion of the company's biologics footprint in emerging markets and licensing agreements boosted the revenue further, she added.
"The acceptance of our proposed biosimilar Trastuzumab filing for review by EMA was a critical milestone this quarter. This is our second filing in EU. The tentative USFDA approval for Rosuvastatin calcium tablets heralds our entry into the US generics market," Ms Mazumdar-Shaw said.
During the quarter, Biocon's facilities in India successfully completed regulatory audits by international agencies like the US drug regulator and MCC South Africa, the company said.
Suresh Subramanian was appointed as senior vice president and head of branded formulations-India business during the quarter, it added.
Shares in Biocon ended 2.04 per cent lower at Rs 980.25 apiece on the BSE, whose benchmark Sensex index finished up 0.52 per cent.
Follow NDTV for latest election news and live coverage of assembly elections 2019 in Maharashtra and Haryana.
Subscribe to our YouTube channel, like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.